Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Neoadjuvant Therapy for NSCLC with TPS ≥ 50%
NCT06195683Phase 2Active, not recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Cancer Hospital. Started Dec 2023; status: active, not recruiting.
02
Drugs
serplulimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06195683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06195683.